[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356395-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356395-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-vaccination-for-active-induction-of-t-cell-immunity-against-cancer-commentary","Therapeutic vaccination for active induction of T cell immunity against cancer - Commentary","","Therapeutic vaccines encompass DNA, mRNA, protein-loaded antigen-presenting cell, synthetic long peptide (SLP), and recombinant virus platforms. Only two therapeutic cancer vaccines were FDA-approved in the past 40 years: sipuleucel-T for hormone-resistant metastatic prostate cancer and zopapogene imadenovec for HPV-6/11-associated recurrent respiratory papillomatosis. Recent DNA, mRNA, and SLP approaches against mutation-derived neoantigens show strong T-cell immunogenicity and clinical activity, with benefits often enhanced by immune checkpoint inhibition and biomarker-guided combination strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-vaccination-for-active-induction-of-t-cell-immunity-against-cancer-commentary/356395/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-vaccination-for-active-induction-of-t-cell-immunity-against-cancer-commentary/356395.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which therapeutic vaccine platforms are discussed in the abstract?","Question",{"text":63,"@type":64},"The abstract lists DNA, mRNA, protein-loaded antigen-presenting cell, synthetic long peptide (SLP), and recombinant virus platforms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What two therapeutic cancer vaccines were FDA-approved over the past 40 years?",{"text":68,"@type":64},"Sipuleucel-T was approved in 2010 for hormone-resistant metastatic prostate cancer, and zopapogene imadenovec was approved in 2025 for recurrent respiratory papillomatosis.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are combination therapies often needed in advanced recurrent/metastatic cancer?",{"text":72,"@type":64},"The text states that late-stage disease requires combinations with surgery and/or chemotherapy or with immune checkpoint inhibitors to counter immunosuppressive influences in the tumor microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356395,1790238693,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":55,"preview_page_count":33,"preview_urls":144},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Open access  \nTo cite: Melief CJM. Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years. Journal for ImmunoTherapy of Cancer 2026;14:e010838 . doi:10.1136/jitc-2024-010838  \nAccepted 10 February 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nLeiden University Medical Center, Leiden, The Netherlands  \nCorrespondence to  \nDr Cornelis J M Melief;  \n[cornelismelief1943@gmail.com](cornelismelief1943@gmail.com)  \nCommentary  \nTherapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years  \nCornelis J M Melief   \nABSTRACT  \nTherapeutic vaccines include DNA, mRNA, protein-loaded antigen-presenting cell, synthetic long peptide (SLP) and recombinant virus platforms. Only two therapeutic vaccines for neoplastic disease were approved by the Food and Drug Administration in the past 40 years: sipuleucel-T, approved in 2010 for hormone-resistant metastatic prostate cancer and targeting prostate acid phosphatase; and zopapogene imadenovec, approved in 2025 for recurrent respiratory papillomatosis, a rare, non-malignant but often invalidating disease caused by human papillomavirus (HPV) type 6 or type 11. In the last decade, DNA, mRNA and SLP vaccines directed against mutation-derived neoantigens have shown strong immunogenicity for T cells and clinical activity with or without additional immune checkpoint inhibition. Vaccine monotherapy is effective in premalignant disorders caused by high-risk HPV16 and virus-negative colonic polyps. Treatment of bulky or recurrent/metastatic (R/M) disease requires combination with surgery and/or chemotherapy or combination with an immune checkpoint inhibitor such as PD-1 blocker. In a recent study, adjuvant treatment with neoantigen-specific mRNA vaccine plus PD-1 blocker led to less melanoma recurrence than PD-1 blocker alone. In another randomized study, patients with R/M HPV16+ head and neck cancer only benefited from the combination of HPV16-specific SLP vaccine and a PD-1 blocker if they had high pretreatment PD-L1 biomarker expression in cancer tissue. Increasingly, biomarker-guided therapy is recommended.  \nINTRODUCTION  \nPreventive vaccination against infectious diseases is a cornerstone of modern society and largely relies on the induction of virusneutralizing or bactericidal antibodies aided by complement and innate immune cells. These usually operate in a virgin landscape not encumbered by undesirable immunoregulation. However, therapeutic vaccination against diseased cells and tissues relies on the induction of effector T cells with the capacity to eradicate the affected cells in a situation compromised by immunosuppressive mechanisms that abound in the tissue microenvironment of the afflicted tissues. Nowhere is this more visible than in the tumor microenvironment (TME) of established  \ncancers, where a variety of immunosuppressive and immune-evasion mechanisms abound.1 Early studies showed the robust power ofT cells in the eradication of murine tumorsin combination with cyclophosphamide2 3 or interleukin-2.4 This soon led to successful therapeutic vaccination against defined tumor-associated T cellepitopes for established murine tumors.1 The importance of antigen-presenting dendritic cells (DC) for the induction of effective therapeutic T cells was shown early on.5 Therapeutic vaccines include DNA, mRNA, protein-loaded antigenpresenting cell, synthetic long peptide (SLP) and recombinant virus platforms.1 As a rule, the success of therapeutic cancer vaccination as monotherapy depends on striking early, such as in premalignant disease or in minimal residual disease following surgery. Success in patients with late-stage recurrent/metastatic (R/M) disease depends on the use of appropriate combinations of therapeutic vaccination with treatments that alleviate the stron","cbCailR013THA1g2","https://ap.wps.com/l/cbCailR013THA1g2","pdf",235627,"English","# Abstract\n## Therapeutic vaccine platforms and clinical approvals\n## Neoantigen-targeted vaccines and combination strategies\n## Biomarker-guided therapy\n# Introduction\n## Limits of preventive vaccination versus therapeutic vaccination\n## Tumor microenvironment immunosuppression\n## Antigen-presenting dendritic cells and platform overview\n# Success as monotherapy in premalignant disease\n## HPV-related premalignant conditions\n## Colonic polyps and MUC-1 peptide vaccination\n## Preventive virus vaccines and therapeutic vaccine gaps\n# FDA approval for recurrent respiratory papillomatosis","[{\"question\":\"Which therapeutic vaccine platforms are discussed in the abstract?\",\"answer\":\"The abstract lists DNA, mRNA, protein-loaded antigen-presenting cell, synthetic long peptide (SLP), and recombinant virus platforms.\"},{\"question\":\"What two therapeutic cancer vaccines were FDA-approved over the past 40 years?\",\"answer\":\"Sipuleucel-T was approved in 2010 for hormone-resistant metastatic prostate cancer, and zopapogene imadenovec was approved in 2025 for recurrent respiratory papillomatosis.\"},{\"question\":\"Why are combination therapies often needed in advanced recurrent/metastatic cancer?\",\"answer\":\"The text states that late-stage disease requires combinations with surgery and/or chemotherapy or with immune checkpoint inhibitors to counter immunosuppressive influences in the tumor microenvironment.\"}]","Therapeutic vaccination for active induction of T cell immunity against cancer - Commentary | PDF",1790125162,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/933196835266c895acfdf733ed14516c.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b59b34c4ba5ce4e56c7035054b3cde63.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9267e23bd28adb3af1656f1884e2e5f1.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a03a0b329e9d15353a0cdb2da70ca2cf.webp",980,1306]